Beclomethasone is an inhaled corticosteroid used to prevent asthma symptoms. It reduces airway inflammation.
Also known as: beclometasona dipropionato, becotide, beklazin
DailyMed/FDA — Beconase, Vancenase; EMC-UK — Beclometasone
DailyMed/FDA; EMC-UK
No documented drug–drug interactions for this medicine.
No documented food or drink interactions.
Inhaled corticosteroids may suppress local immunity.
Do not start in untreated active tuberculosis.
DailyMed/FDA; EMC-UK
Inhaled corticosteroid. Limited data. Use minimum effective dose.
Insufficient data. Use only if benefit justifies risk.
Excreted in breast milk in low concentrations. May be used with caution.
Insufficient data.
DailyMed/FDA; EMC-UK
Clinical and educational support tool. The information does not replace a medical prescription or the opinion of a qualified healthcare professional.
Anti-inflammatory inhaled corticosteroid activity. Reduces bronchial reactivity and chronic inflammation.
Binds to intracellular glucocorticoid receptor, inhibits transcription of pro-inflammatory cytokines (IL-1, IL-6, TNF-α) and increases lipocortin-1 transcription. Local pulmonary effect with low systemic activity.
Rapid pulmonary absorption (40-50% of inhaled dose). Systemic bioavailability: 10-20%.
Metabolised by pulmonary esterases to B-17-MP (inactive). Minor hepatic metabolism by CYP3A4.
Pulmonary: 6 h. Systemic: 2.7 h.
Medicines from the same therapeutic group (ATC classification) or the same pharmacological class.
